Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary safety results from the phase II LIGHT study

Published 2021 View Full Article

Authors

Keywords

Journal

GYNECOLOGIC ONCOLOGY

Volume 162, Issue -, Pages S67-S68

Publisher

Elsevier BV

Online

2021-08-18

DOI

10.1016/s0090-8258(21)00770-8

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

GYNECOLOGIC ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Ask a Question. Answer a Question.